Image of DLBS3233 extract, a novel insulin sensitizer with negligible risk of hypoglycemia: A phase-I study

LITERATURE

DLBS3233 extract, a novel insulin sensitizer with negligible risk of hypoglycemia: A phase-I study


DLBS3233 is a standardized extract combination of two Indonesian herbals (Lagerstroemia speciosa L. and Cinnamomum burmanii L.) developed by a patented extraction-technology. DLBS3233 has been proven pre-clinically to have a glucose lowering activity. This Phase 1 clinical study evaluated the safety of DLBS3233 in comparison with the negative-control and pioglitazone 30 mg (active control) in healthy volunteers. In this randomized, open-labeled, Latin-square-designed clinical study consisting of 7 groups of treatment, DLBS3233 capsules were given at doses of 50, 100, 200, 300, 400 mg in each group, respectively.


Availability

Inlacin-001Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Int J Diabetes & Metab (2012) 21:13-20
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous